z-logo
open-access-imgOpen Access
Lesch-Nyhan Syndrome: Models, Theories, and Therapies
Author(s) -
Scott C. Bell,
Ilaria Kolobova,
Liam Crapper,
Carl Ernst
Publication year - 2016
Publication title -
molecular syndromology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.609
H-Index - 36
eISSN - 1661-8777
pISSN - 1661-8769
DOI - 10.1159/000449296
Subject(s) - lesch–nyhan syndrome , dystonia , hypoxanthine guanine phosphoribosyltransferase , phenotype , medicine , disease , induced pluripotent stem cell , genome editing , bioinformatics , neuroscience , crispr , intellectual disability , genetics , biology , psychiatry , gene , pathology , embryonic stem cell , mutant
Lesch-Nyhan syndrome (LNS) is a rare X-linked disorder caused by mutations in HPRT1, an important enzyme in the purine salvage pathway. Symptoms of LNS include dystonia, gout, intellectual disability, and self-mutilation. Despite having been characterized over 50 years ago, it remains unclear precisely how deficits in hypoxanthine and guanine recycling can lead to such a profound neurological phenotype. Several studies have proposed different hypotheses regarding the etiology of this disease, and several treatments have been tried in patients, though none have led to a satisfactory explanation of the disease. New technologies such as next-generation sequencing, optogenetics, genome editing, and induced pluripotent stem cells provide a unique opportunity to map the precise sequential pathways leading from genotype to phenotype.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom